WATERTOWN, Mass.–(BUSINESS WIRE)– Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating small
molecule drugs for viral infections and liver diseases, today announced
that it plans to report its financial results for its fiscal first
quarter ended December 31, 2018 after the U.S. markets close on February
6, 2019. Enanta management will host a conference call at 4:30 p.m. ET
to discuss these results and provide an update on Enanta’s business,
including its research and development pipeline.
Conference Call and Webcast Information
Enanta will host a
conference call and webcast on February 6 at 4:30 p.m. ET. To
participate in the live conference call, please dial (855) 840-0595 in
the U.S. or (518) 444-4814 for international callers. A replay of the
conference call will be available starting at approximately 7:30 p.m. ET
on February 6, 2019, through 11:59 p.m. ET on February 8, 2019 by
dialing (855) 859-2056 from the U.S. or (404) 537-3406 for international
callers. The passcode for both the live call and the replay is 1190228.
A live audio webcast of the call and replay can be accessed by visiting
the “Events and Presentation” section on the “Investors” page of
Enanta’s website at www.enanta.com.
About Enanta Pharmaceuticals, Inc.
Enanta Pharmaceuticals is
using its robust, chemistry-driven approach and drug discovery
capabilities to become a leader in the discovery and development of
small molecule drugs for the treatment of viral infections and liver
diseases. Enanta’s research and development efforts are currently
focused on the following disease targets: respiratory syncytial virus
(RSV), non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis
(PBC), and hepatitis B virus (HBV). Please visit www.enanta.com
for more information.
Enanta’s research and development activities are currently funded by
royalties from HCV products developed under its collaboration with
AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is now
sold by AbbVie in numerous countries as part of its newest treatment for
chronic hepatitis C virus (HCV) infection. This leading HCV regimen is
sold under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.)
Source: Enanta Pharmaceuticals, Inc.